Literature DB >> 18267076

Control of chemokine-guided cell migration by ligand sequestration.

Bijan Boldajipour1, Harsha Mahabaleshwar, Elena Kardash, Michal Reichman-Fried, Heiko Blaser, Sofia Minina, Duncan Wilson, Qiling Xu, Erez Raz.   

Abstract

Primordial germ cell (PGC) migration in zebrafish is directed by the chemokine SDF-1a that activates its receptor CXCR4b. Little is known about the molecular mechanisms controlling the distribution of this chemoattractant in vivo. We demonstrate that the activity of a second SDF-1/CXCL12 receptor, CXCR7, is crucial for proper migration of PGCs toward their targets. We show that CXCR7 functions primarily in the somatic environment rather than within the migrating cells. In CXCR7 knocked-down embryos, the PGCs exhibit a phenotype that signifies defects in SDF-1a gradient formation as the cells fail to polarize effectively and to migrate toward their targets. Indeed, somatic cells expressing CXCR7 show enhanced internalization of the chemokine suggesting that CXCR7 acts as a sink for SDF-1a, thus allowing the dynamic changes in the transcription of sdf-1a to be mirrored by similar dynamics at the protein level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18267076     DOI: 10.1016/j.cell.2007.12.034

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  264 in total

1.  Secreted CXCL12 (SDF-1) forms dimers under physiological conditions.

Authors:  Paramita Ray; Sarah A Lewin; Laura Anne Mihalko; Sasha-Cai Lesher-Perez; Shuichi Takayama; Kathryn E Luker; Gary D Luker
Journal:  Biochem J       Date:  2012-03-01       Impact factor: 3.857

2.  CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination.

Authors:  Jigisha R Patel; Erin E McCandless; Denise Dorsey; Robyn S Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

3.  Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis.

Authors:  Kevin S Carbajal; Christopher Schaumburg; Robert Strieter; Joy Kane; Thomas E Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

4.  The CXCR7 chemokine receptor promotes B-cell retention in the splenic marginal zone and serves as a sink for CXCL12.

Authors:  Hongsheng Wang; Natalie Beaty; Sophia Chen; Chen-Feng Qi; Marek Masiuk; Dong-Mi Shin; Herbert C Morse
Journal:  Blood       Date:  2011-11-22       Impact factor: 22.113

5.  Use of target protector morpholinos to analyze the physiological roles of specific miRNA-mRNA pairs in vivo.

Authors:  Alison A Staton; Antonio J Giraldez
Journal:  Nat Protoc       Date:  2011-12-01       Impact factor: 13.491

Review 6.  Cell-cell signaling interactions coordinate multiple cell behaviors that drive morphogenesis of the lateral line.

Authors:  Andy Aman; Tatjana Piotrowski
Journal:  Cell Adh Migr       Date:  2011 Nov-Dec       Impact factor: 3.405

7.  The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.

Authors:  Stéphanie Gravel; Camille Malouf; Philip E Boulais; Yamina A Berchiche; Shinya Oishi; Nobutaka Fujii; Richard Leduc; Daniel Sinnett; Nikolaus Heveker
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

8.  Carboxy-terminus of CXCR7 regulates receptor localization and function.

Authors:  Paramita Ray; Laura Anne Mihalko; Nathaniel L Coggins; Pranav Moudgil; Anna Ehrlich; Kathryn E Luker; Gary D Luker
Journal:  Int J Biochem Cell Biol       Date:  2012-01-25       Impact factor: 5.085

9.  The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo.

Authors:  Hengwei Zhang; Lei Yang; Xuyong Teng; Zhangyi Liu; Chenxi Liu; Lei Zhang; Zhen Liu
Journal:  Tumour Biol       Date:  2015-09-17

10.  CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer.

Authors:  Samia M O'Bryan; J Michael Mathis
Journal:  J Cancer Ther       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.